OptiNose Nasdaq IPO

12/6/2018

IPO

Status:

Announced

Date:

12/6/2018

Overview:

OptiNose has undertaken its IPO on Nasdaq.
The company and its stockholders have raised $120.2 million.
OptiNose has offered 2,875,000 shares for sale, while the other 2,875,000 were sold by selling stockholders.
Jefferies and Piper Jaffray have acted as underwriters.
OptiNose is a pharmaceutical company focused on treatments for ear, nose and throat allergies.

Katrin Kostadinova - Data analyst

Jurisdiction:

United States

Deal type:

IPO

Practice area:

Capital markets : Equity

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firm:

Hogan Lovells

Party: OptiNose (Issuer)

Lawyers: Steve Abrams, Steven Kaufman

Related deals